PTJ
PETX

Paul Tudor Jones’s Aratana Therapeutics, Inc. PETX Stock Holding History

Paul Tudor Jones’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,179,912
Closed -$16.4M – 1469
2019
Q2 		$16.4M Buy
3,179,912
+3,104,384
+4,110% +$14M 0.47% 20
2019
Q1 		$272K Buy
75,528
+51,299
+212% +$222K 0.01% 891
2018
Q4 		$149K Buy
24,229
+5,423
+29% +$33.1K ﹤0.01% 893
2018
Q3 		$110K Buy
18,806
+8,343
+80% +$41.7K ﹤0.01% 1019
2018
Q2 		$44K Buy
+10,463
New +$52.8K ﹤0.01% 1003
2017
Q2 		– Sell
-56,600
Closed -$300K – 1538
2017
Q1 		$300K Buy
56,600
+43,600
+335% +$294K 0.01% 997
2016
Q4 		$93K Sell
13,000
-18,749
-59% -$152K ﹤0.01% 1312
2016
Q3 		$297K Buy
+31,749
New +$264K 0.01% 1029
2016
Q2 		– Sell
-36,700
Closed -$203K – 2050
2016
Q1 		$203K Sell
36,700
-900
-2% -$3.38K 0.01% 1504
2015
Q4 		$210K Buy
+37,600
New +$248K 0.01% 1421
2014
Q2 		– Sell
-10,000
Closed -$186K – 1409
2014
Q1 		$186K Buy
+10,000
New +$200K 0.01% 1057

Other funds holding PETX

DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $8.83B AUM 38.5% 1-Year Est. Return

Paul Tudor Jones's PETX Position: Q3 2019 in Review

Paul Tudor Jones sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 3,179,912 shares — an estimated $16.4M sold.

Paul Tudor Jones first reported a position in PETX in Q1 2014 and held it in 11 quarters. The position peaked at $16.4M in Q2 2019. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.

  • Paul Tudor Jones reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Paul Tudor Jones sold 3,179,912 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $16.4M.
  • Paul Tudor Jones first reported a position in Aratana Therapeutics, Inc. in Q1 2014 and held it in 11 quarters.
  • Paul Tudor Jones's Aratana Therapeutics, Inc. position peaked at $16.4M in Q2 2019.
  • 2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.

Based on Tudor Investment Corp's 13F filing for Q3 2019, filed 14 Nov 2019.